What's Happening?
Latigo Biotherapeutics, a clinical-stage biopharmaceutical company, has appointed Todd Smith as an independent director on its board. Smith, currently the CEO of Corium, brings over 30 years of experience in the biopharmaceutical industry, with expertise
in commercial operations and product launches. His appointment is expected to enhance Latigo's strategic direction as it develops non-opioid pain medicines. Smith's extensive background in launching innovative products and building high-performing organizations is seen as a valuable asset to Latigo's mission of delivering effective pain therapies.
Why It's Important?
The appointment of Todd Smith to Latigo Biotherapeutics' board is significant as it brings seasoned leadership to the company at a crucial time. With a focus on developing non-opioid pain treatments, Latigo stands to benefit from Smith's experience in commercializing biopharmaceutical products. His strategic insights could accelerate the company's efforts to bring innovative pain management solutions to market, addressing a critical need for non-addictive pain relief options. This move may also strengthen Latigo's position in the competitive biopharmaceutical landscape.
